Emalfarb, who also discussed the firm's second quarter earnings, says this pharma company is aligned with Dyadic's work, and it has its own division focused on using microbial organisms to replace Chinese hamster ovary cells.
Investor deep dive
Dyadic International on course to disrupt the status quo in manufacturing biologic vaccines and drugs
Full interview: Dyadic International reveals newest research collaboration
Quick facts: Dyadic International Inc
Market Cap: $176.22 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE